The University of Chicago Header Logo

Connection

Mark J. Ratain to Carcinoma, Neuroendocrine

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Carcinoma, Neuroendocrine.
Mark J. Ratain
Connection Strength
0.024
Carcinoma, Neuroendocrine
  1. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.